Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Menopause
Interventions
Premarin® (oral) vs. Alora® (transdermal)
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
42 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cardiometabolic Consequences of the Loss of Ovarian Function

NCT06264882
Conditions
Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions
Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
FHA (Functional Hypothalamic Amenorrhea)
Interventions
Romosozumab, Placebo, Zoledronic acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 30 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Conditions
Prostate, Cancer, Hormonal Cycling
Interventions
GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Results available

A Treatment Study for Premenstrual Syndrome (PMS)

NCT00001259
Conditions
Premenstrual Syndrome, Menstruation Disturbances
Interventions
Leuprolide, Estradiol Patches, Progesterone, Placebo patch, Placebo injection, Placebo suppository
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Cancer, Prostate Neoplasms
Interventions
Leuprolide or goserelin, Transdermal estradiol
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Seattle, Washington
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Pregnancy-associated Hormones on THC Metabolism in Women

NCT04374773
Conditions
Pregnancy Related, Cannabis Use
Interventions
Dronabinol
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC

NCT00789802
Conditions
Contraception, Bleeding
Interventions
transdermal estradiol, naproxen, oral placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Follicle Stimulating Hormone Glycosylation, Urinary FSH21/FSH24 Ratio, Estradiol Effect
Interventions
Estradiol Transdermal Product
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women

NCT02042196
Conditions
Menopause, Aging
Interventions
KUVAN, Placebo, Cetrotide, Climara, Placebo transdermal patch
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

NCT01236768
Conditions
Contraception
Interventions
AG200-15, Levora
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more
Conditions
HIV Infection, Menopause
Interventions
Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Role of Menopause in Thermoregulation

NCT06798571
Conditions
Menopause, Aging
Interventions
Elagolix Oral Tablet, Estradiol patch, cellulose placebo, placebo patch
Drug · Other
Lead sponsor
Penn State University
Other
Eligibility
42 Years to 64 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

NCT06866119
Conditions
Primary Ovarian Insufficiency, Premature Menopause, Metabolic Complications, Endothelial Function (FMD), Estrogen Replacement Therapy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Ovulation
Interventions
NES/E2 gel
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Recruiting Phase 4 Interventional Accepts healthy volunteers

Cyclic vs. Constant Estradiol: Regimens' Effects on Brain Health

NCT07831499
Conditions
Menopause, Healthy Adult, Brain, Postmenopausal
Interventions
Cyclic Estradiol, Continuous Estradiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
38 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Primary Ovarian Insufficiency: Phenotype and Optimal Treatment

NCT03568708
Conditions
Primary Ovarian Insufficiency
Interventions
Transdermal Estrogen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

NCT04597099
Conditions
PCOS, Polycystic Ovary Syndrome
Interventions
Micronized progesterone, Placebo, Flutamide, Estradiol patch
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Anorexia Nervosa
Interventions
Transdermal estrogen, Placebos
Drug
Lead sponsor
Pouneh K. Fazeli, MD
Other
Eligibility
19 Years to 45 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Polycystic Ovary Syndrome
Interventions
Estradiol
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

NCT00837616
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 B estradiol orally, 17 B estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Jacksonville, Florida • Philadelphia, Pennsylvania
Conditions
Hypogonadism, Gender Identity Dysphoria
Interventions
Fortesta, Estradiol
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland